.Nature Medication, Released online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the empirical SCRUM-Japan GOZILA study, after a median consequence of 11 months, individuals with metastatic stomach growths that received biomarker-matched therapies based on circulating tumor DNA profiling revealed a greater clinical advantage than those getting incomparable treatment.